What is Soligenix Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Soligenix's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.42.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Soligenix could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Soligenix's Cash-to-Debt or its related term are showing as below:
SNGX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.31 Med: 9.71 Max: No Debt
Current: 2.42
During the past 13 years, Soligenix's highest Cash to Debt Ratio was No Debt. The lowest was 1.31. And the median was 9.71.
Soligenix Cash-to-Debt Historical Data
The historical data trend for Soligenix's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Soligenix Cash-to-Debt Chart
|
Soligenix Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
42.69 |
1.78 |
2.61 |
1.31 |
2.42 |
|
Soligenix Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.31 |
1.11 |
4.20 |
3.24 |
2.42 |
Competitive Comparison of Soligenix's Cash-to-Debt
For the Biotechnology subindustry, Soligenix's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soligenix's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soligenix's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Soligenix's Cash-to-Debt falls into.
Soligenix Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Soligenix's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Soligenix's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soligenix (Soligenix) Business Description
Traded in Other Exchanges
N/A
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
| Timothy R. Cote |
director |
3529 TILDEN STREET, NW, WASHINGTON DC 20008 |
| Richard Straube |
officer: CMO |
29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
| Christopher Schaber |
director, officer: Chairman, CEO and President |
29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
| Jonathan L. Guarino |
officer: Chief Financial Officer |
100 WELLESLEY WAY, FREEHOLD NJ 07728 |
| Oreola Donini |
officer: CSO |
29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
| Robert J. Rubin |
director |
7901 SPRINGER ROAD, BETHESDA MD 20817 |
| Anthony Gregg Lapointe |
director |
PO BOX 83216, GAITHERSBURG MD 20883-3216 |
| Diane L. Parks |
director |
29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
| Jerome B Zeldis |
director |
8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
| Mark E. Pearson |
director, 10 percent owner |
3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128 |
| Preta Martina Cavazza |
other: Former 10% Owner |
VIA SUDAFRICA 20, ROME L6 00144 |
| Enrico Cavazza |
other: Former 10% Owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Silvia Cavazza |
other: Former 10% Owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Francesca Cavazza |
other: Former 10% Owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Spa Essetifin |
10 percent owner |
VIA SUDAFRICA 20, ROME L6 00144 |
Soligenix (Soligenix) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNGX has been successfully added to your